Chronic News and Research

RSS

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has reacquired all development and commercial rights to its high-mobility group box protein 1 (HMGB1) related technology from MedImmune, LLC.

6 Jul 2010

Three Rivers Pharmaceuticals receives FDA expanded labeling for INFERGEN

Three Rivers Pharmaceuticals, LLC, today received expanded labeling from the U.S. Food and Drug Administration (FDA) to include daily use of INFERGEN (Consensus Interferon) in combination with ribavirin (RBV) for retreatment of chronic hepatitis C patients. The expanded labeling targets hepatitis C patients who need retreatment.

6 Jul 2010

Training for first responders on antidote for acute cyanide poisoning from fire smoke

Since January 1, 2010 the CPTC has tracked 1,100 civilians treated for smoke inhalation, 413 smoke inhalation deaths, and 125 firefighters who were transported for smoke inhalation treatment. Contrary to popular belief, whether a civilian or a firefighter, smoke inhalation isn't a minor injury - it's deadly.

6 Jul 2010

Breathing system filters used in anaesthesia allow passage of bacterial, yeast infections

Doctors have highlighted potential problems with the breathing system filters used in anaesthesia, including intensive care units, after demonstrating that they don't provide protection from harmful bacteria and yeast when they become wet.

6 Jul 2010

Health Council of Canada applauds B.C. initiative for integrated primary and community care

The Health Council of Canada applauds the British Columbia Ministry of Health Services and the B.C. Medical Association on their June 24, 2010 announcement of $137 million toward integrated primary and community care that will connect every resident with a family doctor by 2015, starting with the province's most vulnerable citizens - high needs patients, frail seniors and patients with chronic diseases.

6 Jul 2010

A20 protein plays protective role in diseases associated with chronic bowel inflammation: Scientists

Scientists associated with VIB (Flanders Institute for Biotechnology) and Ghent University have discovered that A20 protein plays an important protective role in diseases associated with chronic bowel inflammation. This makes A20 into a promising therapeutic target for the development of new anti-inflammatory drugs.

5 Jul 2010

Mobile phone application to support self-management of health and well-being

The increasing prevalence of lifestyle-related health risks coupled with the lack of resources in preventative healthcare calls for novel and cost-efficient methods for supporting citizens in their independent health and well-being management. Behaviour modification is an efficient way of preventing chronic diseases and other lifestyle-related health problems, provided that the healthy behaviours are sustained over the long term.

5 Jul 2010

Impax confirms challenge of patent relating to RENVELA

Impax Laboratories, Inc. today confirms that it has initiated a challenge of a patent listed by Genzyme Corporation in connection with RENVELA® (sevelamer carbonate for suspension), 2.4 g and 0.8 g.

3 Jul 2010

Eli Lilly, Alnara sign definitive merger agreement

Eli Lilly and Company and Alnara Pharmaceuticals, Inc. today announced they have signed a definitive merger agreement whereby Lilly will acquire Alnara, a privately held biotechnology company developing protein therapeutics for the treatment of metabolic diseases. Alnara's lead product in development is liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT).

2 Jul 2010

PhenotypeIT launches integrated Corporate Health and Wellness Management Platform

PhenotypeIT, Inc. announced today the launch of its PhIT™ platform, the first truly integrated Corporate Health and Wellness Management Platform that predicts disease and chronic health conditions before their onset and provides critical aggregated data to employers to reduce costs. The PhIT platform accurately assesses the impact of current and future health conditions, and assesses the cost implications of these conditions and related loss of productivity for the employer.

2 Jul 2010

Plant extract effective against ulcerative colitis in mice

A South Dakota State University scientist's research shows an extract made from a food plant in the Brassica family was effective in alleviating signs of ulcerative colitis, an inflammatory bowel condition, in mice.

2 Jul 2010

Heart patients with transient kidney dysfunction have no serious complications

New research led by UC Health cardiologists shows that while short-term worsening kidney function is frequent among patients with heart failure, these patients also have better outcomes than those who have persistent kidney failure

2 Jul 2010

UCLA study highlights traffic-related asthma flares in urban areas

A new academic study led by UCLA scientists has found that even brief exposure to ultrafine pollution particles near a Los Angeles freeway is potent enough to boost the allergic inflammation that exacerbates asthma.

2 Jul 2010

Allogeneic stem cell transplant holds promise for treatment-resistant chronic lymphocytic leukemia

Allogeneic (donor-derived) stem cell transplant (alloSCT) may be a promising option for patients with treatment-resistant chronic lymphocytic leukemia (CLL), regardless of the patient's underlying genetic abnormalities, according to the results of a study published online today in Blood, the journal of the American Society of Hematology.

2 Jul 2010

FDA approves Purdue's Butrans Transdermal System CIII for management of chronic pain

Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Butrans™ (buprenorphine) Transdermal System CIII for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Butrans Transdermal System is an analgesic product that delivers continuous release of medication for seven days.

2 Jul 2010

Neuros Medical receives $1.5M Applied Research and Technology Development Award from DMRDP

Neuros Medical, Inc., a medical device company announced today they have received notification of award for $1.5 million from the U.S. Department of Defense. The Applied Research and Technology Development Award was provided by the Defense Medical Research and Development Program (DMRDP).

2 Jul 2010

Clinical study proves effectiveness of acupuncture for heart patients

Acupuncture can improve exercise tolerance in patients suffering from chronic heart failure. This was determined in a clinical pilot study by the team headed by Dr. Johannes Backs, physician and study director at the Department of Internal Medicine III (Cardiology, Angiology, and Pneumology - Medical Director: Professor Dr. Hugo Katus) of Heidelberg University Hospital.

2 Jul 2010

High fructose diet can cause hypertension

People who eat a diet high in fructose, in the form of added sugar, are at increased risk of developing high blood pressure, or hypertension, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

2 Jul 2010

First analyses on impact of Medicare Part D presented at UMB's 2010 Academy/Health Annual Meeting

Some of the first analyses on the impact of Medicare Part D, as well as new insights on drug adherence patterns by chronic disease patients, will be presented today and tomorrow at the 2010 Academy/Health Annual Meeting by several University of Maryland, Baltimore teams of pharmaceutical health services researchers.

1 Jul 2010

ESMT CA study: Cutting pharmaceutical prices will reduce number of new medications

Cutting pharmaceutical prices will severely reduce the number of new medications making it to market, according to a groundbreaking independent study from ESMT Competition Analysis. For the first time, the study on 'Pharmaceutical Innovation and Pricing Regulation' clearly models and quantifies the direct link between strict regulation and low innovation.

1 Jul 2010

Chronic News and Research

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Three Rivers Pharmaceuticals receives FDA expanded labeling for INFERGEN

Training for first responders on antidote for acute cyanide poisoning from fire smoke

Breathing system filters used in anaesthesia allow passage of bacterial, yeast infections

Health Council of Canada applauds B.C. initiative for integrated primary and community care

A20 protein plays protective role in diseases associated with chronic bowel inflammation: Scientists

Mobile phone application to support self-management of health and well-being

Impax confirms challenge of patent relating to RENVELA

Eli Lilly, Alnara sign definitive merger agreement

PhenotypeIT launches integrated Corporate Health and Wellness Management Platform

Plant extract effective against ulcerative colitis in mice

Heart patients with transient kidney dysfunction have no serious complications

UCLA study highlights traffic-related asthma flares in urban areas

Allogeneic stem cell transplant holds promise for treatment-resistant chronic lymphocytic leukemia

FDA approves Purdue's Butrans Transdermal System CIII for management of chronic pain

Neuros Medical receives $1.5M Applied Research and Technology Development Award from DMRDP

Clinical study proves effectiveness of acupuncture for heart patients

High fructose diet can cause hypertension

First analyses on impact of Medicare Part D presented at UMB's 2010 Academy/Health Annual Meeting

ESMT CA study: Cutting pharmaceutical prices will reduce number of new medications

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News